Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 202

Similar articles for PubMed (Select 23090986)

1.

Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas.

Jansen NL, Schwartz C, Graute V, Eigenbrod S, Lutz J, Egensperger R, Pöpperl G, Kretzschmar HA, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la Fougère C, Thon N.

Neuro Oncol. 2012 Dec;14(12):1473-80. doi: 10.1093/neuonc/nos259. Epub 2012 Oct 22.

2.

Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas.

Stockhammer F, Thomale UW, Plotkin M, Hartmann C, Von Deimling A.

J Neurosurg. 2007 Apr;106(4):633-7.

PMID:
17432715
3.

11C-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumors.

Saito T, Maruyama T, Muragaki Y, Tanaka M, Nitta M, Shinoda J, Aki T, Iseki H, Kurisu K, Okada Y.

AJNR Am J Neuroradiol. 2013 Jan;34(1):85-91. doi: 10.3174/ajnr.A3173. Epub 2012 Jul 5.

5.

[Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].

Huang L, Jiang T, Yuan F, Li GL, Xu LX, Cui Y.

Zhonghua Zhong Liu Za Zhi. 2011 Oct;33(10):752-8. Chinese.

PMID:
22335907
6.

[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma.

Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, McCoy M, Göbel G, la Fougère C, Virgolini IJ, Trinka E, Jacobs AH, Stockhammer G.

Neuro Oncol. 2013 Mar;15(3):341-51. doi: 10.1093/neuonc/nos300. Epub 2013 Jan 17.

7.

Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases.

Scheie D, Meling TR, Cvancarova M, Skullerud K, Mørk S, Lote K, Eide TJ, Helseth E, Beiske K.

Neuro Oncol. 2011 Nov;13(11):1225-33. doi: 10.1093/neuonc/nor114. Epub 2011 Aug 19.

8.

FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading.

Pöpperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K.

Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1933-42. Epub 2007 Sep 1.

PMID:
17763848
9.

Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.

Huang L, Jiang T, Yuan F, Li GL, Cui Y, Liu EZ, Wang ZC.

Neuropathol Appl Neurobiol. 2009 Aug;35(4):367-79. doi: 10.1111/j.1365-2990.2008.01002.x. Epub 2008 Nov 18.

PMID:
19019173
10.

Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy.

Calcagni ML, Galli G, Giordano A, Taralli S, Anile C, Niesen A, Baum RP.

Clin Nucl Med. 2011 Oct;36(10):841-7. doi: 10.1097/RLU.0b013e3182291b40.

PMID:
21892031
11.

Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas.

Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, Geisler J, la Fougere C, Lutz J, Linn J, Kreth S, von Deimling A, Tonn JC, Kretzschmar HA, Pöpperl G, Kreth FW.

Neuro Oncol. 2011 Mar;13(3):307-16. doi: 10.1093/neuonc/noq196. Epub 2011 Feb 3.

12.

Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients.

Jansen NL, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, Niyazi M, Drexler M, Bartenstein P, Schnell O, Tonn JC, Thon N, Kreth FW, la Fougère C.

J Nucl Med. 2014 Feb;55(2):198-203. doi: 10.2967/jnumed.113.122333. Epub 2013 Dec 30.

13.

Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.

Gresner SM, Rieske P, Wozniak K, Piaskowski S, Jaskolski DJ, Skowronski W, Golanska E, Sikorska B, Liberski PP.

Clin Neuropathol. 2006 Jan-Feb;25(1):18-24.

PMID:
16465770
14.

Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment?

Ramirez C, Bowman C, Maurage CA, Dubois F, Blond S, Porchet N, Escande F.

Neuro Oncol. 2010 May;12(5):490-9. doi: 10.1093/neuonc/nop071. Epub 2010 Feb 14.

15.

Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas.

Stockhammer F, Plotkin M, Amthauer H, van Landeghem FK, Woiciechowsky C.

J Neurooncol. 2008 Jun;88(2):205-10. doi: 10.1007/s11060-008-9551-3.

PMID:
18317691
16.

Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FET-PET.

Niyazi M, Jansen N, Ganswindt U, Schwarz SB, Geisler J, Schnell O, Büsing K, Eigenbrod S, la Fougère C, Belka C.

J Neurooncol. 2012 Dec;110(3):389-95. doi: 10.1007/s11060-012-0980-7. Epub 2012 Oct 4.

PMID:
23054562
17.

Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.

Pöpperl G, Götz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K.

Eur J Nucl Med Mol Imaging. 2004 Nov;31(11):1464-70. Epub 2004 Jul 10.

PMID:
15248032
18.

Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?

Pöpperl G, Kreth FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K.

J Nucl Med. 2006 Mar;47(3):393-403. Erratum in: J Nucl Med. 2006 May;47(5):806.

19.

Prediction of pathology and survival by FDG PET in gliomas.

Padma MV, Said S, Jacobs M, Hwang DR, Dunigan K, Satter M, Christian B, Ruppert J, Bernstein T, Kraus G, Mantil JC.

J Neurooncol. 2003 Sep;64(3):227-37.

PMID:
14558598
20.

[Loss of heterozygosity on chromosomes 1 and 19 in cases of primary brain tumour].

Born PW, Broholm H, Laursen H.

Ugeskr Laeger. 2006 Oct 30;168(44):3813-6. Danish.

PMID:
17118240
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk